Tag: VMT-𝛼-NET

10May 2021 by Ronny Allan 3 Comments

Clinical Trial: Neuroendocrine Tumour (VMT-𝛼-NET) programs

Clinical Trial: Neuroendocrine Tumour (VMT-𝛼-NET) programs

Clinical Trials and Research

Perspective Therapeutics Announces First Neuroendocrine Tumor Patients Dosed with Therapeutic IntentNovember 8, 2023SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), announced today that the first patient was dosed at Washington University in St Louis in the Company's Phase 1/2a trial evaluating the safety and efficacy of [212Pb]VMT-α-NET, a targeted alpha-particle therapy (TAT), in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). The trial is a multi-center, open-label dose escalation, dose expansion study of [212Pb]VMT-α-NET in patients who have not received prior peptide receptor radionuclide therapy (PRRT). Read announcement hereTargeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT)The Company's melanoma (VMT01) and neuroendocrine tumour (VMT-𝛼-NET) programs will then commence Phase 1/2a therapy trials for the treatment of…

Read More

A Spotlight on Neuroendocrine Cancer Syndromes – Carcinoid Syndrome

What is Carcinoid Syndrome? Carcinoid syndrome (CS) is the most frequent hormonal complication accompanying neuroendocrine neoplasms (NENs) and is defined by chronic diarrhoea and/or flushing in the presence of systemic elevated levels of serotonin or its metabolite 5-hydroxyindolacetic acid (5-HIAA). Importantly, other causes of these symptoms should be considered and investigated depending on the clinical presentation. CS […]

Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors – PRRT vs Everolimus

I was delighted to see this clinical trial which looks at the efficacy of PRRT (Lu177) vs the efficacy of Everolimus (Afinitor). The latter is approved for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease (US FDA wording, […]

Opinion: Let’s attack Cancer metaphors

Since I started blogging, I’ve read dozens of articles on the subject of ‘cancer metaphors’ and in particular their use in describing cancer experiences with the words ‘fight’, ‘battle’ and other ‘military’ sounding terms. The authors say that perhaps this is not the best language to use. One author used the term ‘violence’ to describe these […]

A review of November 2023 on RonnyAllan.NET – Living with Neuroendocrine Cancer

November is always busier as I help spread awareness for 10th Nov (remembering that every day is 10th Nov on my site!). I also managed to push out quite a few blogs, some ‘remasters’ from 2014 but with their originality from that time. Others include the ENETS Guideline series, a work in progress. I’m thankful […]

European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for Digestive Neuroendocrine Carcinoma

This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based on recent developments and study results. These recommendations aim to pave the road for more standardized care for our patients resulting in improved outcomes. However, it’s true to say that […]